Summit Wealth Partners LLC lessened its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 10,101 shares of the company’s stock after selling 319 shares during the period. Summit Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,675,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Conquis Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $36,000. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the period. Finally, von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter valued at $49,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
Shares of JNJ opened at $167.90 on Wednesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a market cap of $403.99 billion, a P/E ratio of 17.96, a P/E/G ratio of 2.09 and a beta of 0.41. The business’s fifty day moving average is $154.29 and its 200 day moving average is $155.12. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.10%. Johnson & Johnson’s payout ratio is presently 55.61%.
Analyst Ratings Changes
A number of equities research analysts have commented on JNJ shares. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. UBS Group restated a “buy” rating and issued a $190.00 price objective (up previously from $180.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $172.87.
Check Out Our Latest Analysis on JNJ
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 2 Chinese Stocks That Could Leave U.S. Tech in the Dust
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom
- Find and Profitably Trade Stocks at 52-Week Lows
- 4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.